 Home > Medical News > Latest Medical News > Selective JAK inhibitors receive FDA priority review qualification for treatment of myelofibrosis

Selective JAK inhibitors receive FDA priority review qualification for treatment of myelofibrosis

 Last Update: 2021-06-11
 Source: Internet
 Author: User

Tags

epi side effects

ans 1 2

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On June 1, 2021, CTI BioPharma announced that the US FDA has accepted its new drug application (NDA) for the investigational oral kinase inhibitor pacritinib for the treatment of myelofibrosis patients with severe thrombocytopenia.

Pacritinib is an oral inhibitor that specifically inhibits JAK2, IRAK1 and CSF1R.

This NDA application is based on the positive results of one phase 2 clinical trial and two phase 3 clinical trials of pacritinib.

▲The molecular structure of Pacritinib (photo source: Anypodetos, Public domain, via Wikimedia Commons)

Myelofibrosis is a type of bone marrow cancer that manifests as the formation of fibrous scar tissue, which can lead to severe thrombocytopenia and anemia, weakness, fatigue, and enlargement of the spleen and liver.

Note: The original text has been deleted

Reference materials:

[1] CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for Treatment of Patients with Myelofibrosis.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.